Health
China Sinopharm’s potential COVID-19 vaccine triggers antibodies in clinical trials – CNA
BEIJING: A coronavirus vaccine candidate developed by a unit of China National Pharmaceutical Group (Sinopharm) appeared to be safe and triggered antibody-based immune responses in early and mid-stage trials, researchers said.
BEIJING: A coronavirus vaccine candidate developed by a unit of China National Pharmaceutical Group (Sinopharm) appeared to be safe and triggered antibody-based immune responses in early and mid-stage trials, researchers said.
The potential vaccine has already moved into a late-stage trial, one of a handful of candidates being tested on several thousand people to see if they are effective enough to win regulatory approval.
Advertisement
Advertisement
Sinopharm is testing the potential vaccin…
-
Noosa News20 hours agoCommissioner thanks police officer who threw a speed radar at a car
-
Noosa News18 hours agoNo matter what happens in his Origin debut, history beckons for rookie maroon Robert Toia
-
Noosa News19 hours agoDefence investigation finds Taipan pilot’s actions possibly prevented further fatalities in crash
-
Noosa News19 hours agoGood character references restricted in rape cases in Queensland